Cancer is a global epidemic disease responsible for over ten millions death worldwide. The early diagnosis and the precise treatment with reduced adverse reactions are the main goal worldwide. In this study, we produced, characterized and evaluated (in vitro) in three different cancer cell lines (protaste, breast and melanoma) a radioactive gold nanocluster (R-AuNC) (198Au25(Capt)18). The pharmacokinetics as the influence in the ABC transporter (MRP1 Efflux Transporter Protein) was also evaluated. The results showed that R-AuNC (198Au25(Capt)18) are capable to kill the cancer cells lines of protaste, breast and melanoma. The pharmacokinetics showed a fast clearance and great volume of distribution, confirming the use of R-AuNC as nanomedicine for cancer treatment. Finally, the ABC transporter assay corroborated that the R-AuNC (198Au25(Capt)18) has no risk of being pumped out of cells by this efflux transporter. The results validate the use of gold nanoparticles as therapeutic nanomedicine for cancer treatment.

中文翻译：

---

放射性金纳米团簇（198-AuNCs）对癌细胞系显示出抑制作用。

癌症是一种全球流行病，导致全世界超过千万人死亡。早期诊断和精准治疗，减少不良反应是全世界的主要目标。在这项研究中，我们在三种不同的癌细胞系（前列腺癌、乳腺癌和黑色素瘤）中生产、表征和评估（体外）放射性金纳米团簇 (R-AuNC) (198Au25(Capt)18)。还评估了药代动力学对 ABC 转运蛋白（MRP1 外排转运蛋白）的影响。结果表明，R-AuNC (198Au25(Capt)18) 能够杀死前列腺癌、乳腺癌和黑色素瘤的癌细胞系。药代动力学显示快速清除和大量分布，证实了 R-AuNC 作为纳米药物用于癌症治疗的用途。最后，ABC 转运蛋白分析证实 R-AuNC (198Au25(Capt)18) 没有被这种外排转运蛋白泵出细胞的风险。结果验证了金纳米粒子作为治疗性纳米药物用于癌症治疗的用途。